Tessa Therapeutics Announces Positive Results from CD30 CAR-T Combination Study with Nivolumab in 2nd line Hodgkin Lymphoma Objective response observed in 9/10 patients and complete response observed in 7/10 patientsNo patients proceeded to autologous stem cell transplant (ASCT) as of data cut-off Well tolerated safety...

Tessa Therapeutics’ ‘Off-the-Shelf’ CAR-T Therapy Shows Promising Results in Early-Stage Study of Hodgkin Lymphoma 78% Overall Response Rate (14/18 patients), including seven patients exhibiting a complete response to TT11X allogeneic CAR-T therapySafety data encouraging with no graft-versus-host-disease and no...

Tessa Therapeutics’ Autologous and Allogeneic Cell Therapy Data to be Featured at the 17th International Conference on Malignant Lymphoma, Lugano SINGAPORE, May 30, 2023 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...

Tessa Therapeutics Showcases Positive Clinical Data from Phase 1 Study of “Off the Shelf” CD30 Cell Therapy at 2021 Annual Meeting of American Society of Hematology (ASH) Oral poster presentation highlights data from dose-escalation trial of allogeneic CD30.CAR EBVST cell therapy (TT11X) in patients with relapsed or refractory CD30-positive lymphomas Results...